Health-Related Quality of Life and Cognitive Performance During 12-Month Adjunctive Brivaracetam Treatment in Patients with Focal-Onset Seizures: A Prospective, Observational Study in Europe
Neurology and Therapy · 2025-04 · 14 (2) · 609-625
DOI: 10.1007/s40120-024-00698-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurology and Therapy, online erschienen am 20.02.2025. Verfasst von Eduardo Rubio-Nazabal und 6 weiteren Autor:innen. Beteiligte Einrichtung: Coruna University Hospital, Xubias de Arriba, 84, 15006, A Coruna, Spain. erubialva@gmail.com. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: UCB Pharma.
Abstract (Originalsprache)
INTRODUCTION: This analysis aimed to evaluate patient-related outcomes for health-related quality of life (HRQoL) and cognitive performance in patients (≥ 16 years) with focal-onset seizures (FOS), with/without focal to bilateral tonic-clonic seizures, after initiating adjunctive brivaracetam (BRV) in routine clinical practice. METHODS: A 12-month, prospective, real-world, noninterventional study in nine European countries (EP0077/NCT02687711) was performed. BRV was prescribed per clinical practice and the European Summary of Product Characteristics. The outcomes evaluated were the Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P), the Clinical and the Patient's Global Impression of Change (CGIC and PGIC, respectively), and EpiTrack®. EpiTrack® scores were categorized into cognitive performance categories (excellent: ≥ 39 points; average: 32-38 points; mildly impaired: 29-31 points; significantly impaired: ≤ 28 points). The change in EpiTrack® score was evaluated [improvement: increase in score of ≥ 4 points; no change: change in score of - 2 to 3 points (inclusive); worsening: change in score of at least - 3 points]. RESULTS: Full Analysis Set: 541 patients. 46.6% of patients reported a clinically meaningful improvement in QOLIE-31-P total score from baseline to 12 months; the mean change in total score was + 6.2 points (N = 103). Per CGIC (N = 142) and PGIC (N = 148), respectively, 69.0% and 62.8% of patients had improved in overall condition at 12 months versus baseline, while 3.5% and 8.1% had worsened. EpiTrack® categories at 12 months versus baseline showed improved cognitive performance [baseline (N = 142): significantly impaired 49.3%, mildly impaired 14.8%, average 33.1%, excellent 2.8%; 12 months (N = 61): significantly impaired 36.1%, mildly impaired 4.9%, average 52.5%, excellent 6.6%]. At 12 months, 67.2% of patients showed no significant change from baseline in EpiTrack® score, 23.0% had improved, and 9.8% had worsened (N = 61). CONCLUSION: In patients with predominantly difficult-to-treat FOS, BRV add-on was associated with good HRQoL and cognitive functioning. Cognitive functioning remained stable for 12 months after BRV initiation in most patients; nearly one-quarter experienced significant improvements. At 12 months, 46.6% of patients reported clinically meaningful HRQoL improvements, and most showed an improved overall condition.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Coruna University Hospital, Xubias de Arriba, 84, 15006, A Coruna, Spain. erubialva@gmail.com.
- Academic Center of Epileptology Kempenhaeghe, Maastricht University Medical Center, Sterkselseweg 65, 5591 VE, Heeze, Netherlands.
- UCB, Alfred-Nobel-Straße 10, 40789, Monheim Am Rhein, Germany.
- UCB, 216 Bath Road, Slough, SL1 3WE, UK.
- UCB, Agiou Dimitriou 63, 174 56, Alimos, Greece.
- Kork Epilepsy Centre, Landstr. 1, 77694, Kehl-Kork, Germany.
ORCID-Profile: Eduardo Rubio-Nazabal, Bernhard J Steinhoff
Förderung
- UCB Pharma
Zitieren
APA
Rubio-Nazabal, E., Majoie, M., Schulz, A. L., Brock, F., Leunikava, I., Bourikas, D., & Steinhoff, B. J. (2025). Health-Related Quality of Life and Cognitive Performance During 12-Month Adjunctive Brivaracetam Treatment in Patients with Focal-Onset Seizures: A Prospective, Observational Study in Europe. Neurology and Therapy, 14(2), 609-625. https://doi.org/10.1007/s40120-024-00698-3
Vancouver
Rubio-Nazabal E, Majoie M, Schulz AL, Brock F, Leunikava I, Bourikas D, et al. Health-Related Quality of Life and Cognitive Performance During 12-Month Adjunctive Brivaracetam Treatment in Patients with Focal-Onset Seizures: A Prospective, Observational Study in Europe. Neurology and Therapy. 2025;14(2):609-625. doi:10.1007/s40120-024-00698-3
BibTeX
@article{RubioNazabal2025,
author = {Rubio-Nazabal, Eduardo and Majoie, Marian and Schulz, Anne-Liv and Brock, Fiona and Leunikava, Iryna and Bourikas, Dimitrios and Steinhoff, Bernhard J},
title = {Health-Related Quality of Life and Cognitive Performance During 12-Month Adjunctive Brivaracetam Treatment in Patients with Focal-Onset Seizures: A Prospective, Observational Study in Europe},
journal = {Neurology and Therapy},
year = {2025},
volume = {14},
number = {2},
pages = {609--625},
doi = {10.1007/s40120-024-00698-3}
}
EUVIMED